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Microabstract: 29 
Currently available molecular signatures assess the risk of recurrence and the benefit of 30 
chemotherapy, however these tests may have large intermediate risk groups, limiting their 31 
utilities. We describe a novel 5-gene signature that is a robust prognostic assay that performed 32 
similarly to currently available signatures in concordance analyses. However it identified 33 
significantly fewer patients as intermediate risk, and more as low risk than currently available 34 
assays.  35 
  36 
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on July 18, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3
ABSTRACT 37 
Introduction: Early stage ER+ breast cancer may be treated with chemotherapy in addition to 38 
hormone therapy. Currently available molecular signatures assess the risk of recurrence and the 39 
benefit of chemotherapy, however these tests may have large intermediate risk groups, limiting 40 
their utilities.  41 
Methods: EarlyR prognostic score was developed using integrative analysis of microarray 42 
datasets and FFPE-based qRT-PCR assay and validated in Affymetrix datasets and METABRIC 43 
cohort using Cox proportional hazards models and Kaplan-Meier survival analysis. Concordance 44 
index was used to measure the probability of prognostic score agreement with outcome.  45 
Results: The EarlyR score and categorical risk strata (EarlyR-Low, EarlyR-Int, EarlyR-High), 46 
derived from expression of ESPL1, MKI67, SPAG5, PLK1 and PGR, was prognostic of 8-year 47 
distant recurrence-free interval (DRFI) in Affymetrix (categorical P =3.5 x 10-14; continuous P 48 
=8.8 x10-15) and METABRIC (categorical P <2.2x10-16; continuous P<10-16) datasets of ER+ 49 
breast cancer. Similar results were observed for the breast cancer-free interval endpoint. At most 50 
13% of patients were intermediate risk and at least 66% patients were low-risk in both ER+ 51 
cohorts. EarlyR score was significantly prognostic (DRFI; P<0.001) in both LN-, LN+ patients 52 
and independent from clinical factors. EarlyR and surrogates of current molecular signatures 53 
were comparable in prognostic significance by concordance index.  54 
Conclusions: The five-gene EarlyR score is a robust prognostic assay that identified significantly 55 
fewer patients as intermediate risk, and more as low risk than currently available assays. Further 56 
validation of the assay in clinical trial derived cohorts is ongoing.   57 
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on July 18, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 4
INTRODUCTION 58 
Classification and management of a disease significantly reflects understanding of the disease 59 
condition. Until recently, breast cancer was believed to be a single disease which was treated by 60 
surgical excision followed by chemotherapy, with the addition of tamoxifen for estrogen receptor 61 
positive (ER+) disease. Molecular analysis of breast cancers using gene expression microarrays 62 
resulted in the recognition of breast cancer as a heterogeneous disease in which different 63 
subtypes respond to distinct therapeutic regimens1, 2. In recent years, numerous genomic assays, 64 
including, Oncotype DX®3, Mammaprint®4, 5, Prosigna® (Risk of Recurrence)6, EndoPredict® 65 
7, Breast Cancer Index®8, 9, were developed to help inform physicians’ treatment decisions for 66 
adjuvant therapy. National Comprehensive Cancer Network (NCCN) treatment guidelines for 67 
ER+, HER2-, > 0.5 cm tumors, with no lymph node involvement, recommend Oncotype DX 68 
Recurrence Score (RS) testing, followed by hormone therapy alone for low-risk patients (RS ≤ 69 
18), and hormone therapy and adjuvant chemotherapy for high-risk patients (RS ≥ 31).  70 
Physicians may alternatively use prognostic information from other molecular signatures to 71 
guide treatment. Multiple studies have reported a reduction in the proportion of ER+ patients 72 
receiving chemotherapy concurrent with adoption of Oncotype DX10, 11. 73 
 The impact of such a genomic assay on treatment decisions depends, in part, on the 74 
proportions of patients classified as low risk, high risk or intermediate risk.  The tests listed 75 
above identify approximately 50% of lymph node negative ER+ patients as low risk.  The 76 
Oncotype DX assay has a large intermediate risk group (38% and 40% in two clinical use studies 77 
10, 12, respectively), for which a treatment recommendation is unclear.  78 
Herein, we describe a gene signature “EarlyR” using a novel probe expression analysis 79 
methodology13 for the prognostication of ER+ breast cancer. EarlyR may be applied as a 80 
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continuous score or in low, intermediate and high risk strata. In the ER+, lymph node negative, 81 
HER2- tumors in METABRIC cohort14, EarlyR identified 72%, 12%, 16% as low, intermediate 82 
and high risk, respectively. This is significantly more low risk, and significantly fewer 83 
intermediate risk patients than reported by currently available assays (e.g. Mammaprint and 84 
Oncotype DX15, 16). To build evidence of the clinical utility of the test, we converted it to a 85 
“proof of principle” quantitative real time polymerase chain reaction (RT-PCR)-based assay for 86 
formalin-fixed, paraffin-embedded (FFPE) tissue.  87 
 88 
  89 
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METHODS 90 
Microarray datasets used in this study 91 
The Affymetrix training set used in this study was obtained from the LN- samples in GSE349417 92 
and GSE739018 (Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov). The validation set 93 
was derived from patients from the following datasets: GSE1209319, GSE653220, GSE203421, 94 
GSE1112122, GSE1770523. The CEL files from all series were normalized together and 95 
expression values computed with GCRMA (GC Robust Multi-array Average) package24. Batch 96 
effects were eliminated with the ComBat tools25. 97 
 The patient characteristics of the Affymetrix (training and validation) and METABRIC 98 
cohorts are described in Suppl. Table S1. None of the patients in the Affymetrix cohorts had 99 
received chemotherapy and 46% received hormone therapy. Patients in METABRIC cohort14 100 
were treated with hormone therapy and/or chemotherapy as directed by the treating physician. In 101 
contrast to current practice, hormone therapy was predominately prescribed only for patients 102 
with positive lymph nodes or large tumors (more than 2 cm); only 54% of LN- patients received 103 
hormone therapy. A tumor in METABRIC cohort was considered HER2+ if there was gain in the 104 
number of copies of ERBB2 as assessed using microarray-based copy number analysis14.  105 
 The prognostic significance of EarlyR was studied, as per the STEEP guidelines 26. 106 
Distant recurrence-free interval (DRFI) was defined as the time from surgery to recurrent distant 107 
metastatic breast cancer, and breast cancer free interval (BCFI), defined as the time from surgery 108 
to recurrent distant metastatic breast cancer or loco-regional invasive ipsilateral breast cancer. 109 
Data for both BCFI and DRFI were obtained for patients in the METABRIC cohort 110 
(unpublished). In Affymetrix cohorts the endpoints were described as distant metastasis-free 111 
survival (DMFS). It is unlikely that differences between study-specific endpoints and DRFI 112 
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would result in significant changes in the number of events in these datasets.  Prognostic 113 
significance with respect to DRFI and BCFI was assessed up to 8 years following diagnosis. The 114 
threshold of eight years was chosen based on a prior publication from the Cuzick group showing 115 
that the prognostic utility of current genomic signatures for ER+ breast cancer deteriorates after 8 116 
years 27.  117 
 118 
Translation of the microarray gene set to qRT-PCR platform using formalin-fixed, paraffin-119 
embedded tissues 120 
Sample Selection and Preparation  121 
The Institutional Review Board of Indiana University approved the study. Informed consent 122 
waiver was obtained and only de-identified data was used in the analyses.  123 
Archival formalin-fixed, paraffin-embedded (FFPE) tumor blocks were chosen from 72 patients 124 
with breast cancer at the Indiana University Simon Cancer Center based on their Oncotype DX 125 
RS. Initial real-time quantitative RT-PCR (qRT-PCR) analysis was conducted using 10 samples 126 
of ER+ breast cancers. This was followed by qRT-PCR analysis using customized arrays of 23 127 
cases with high RS, 26 cases with intermediate RS, and 23 cases with low RS. Demographic and 128 
clinical characteristics of the patients were acquired from medical charts (Suppl. Table S2). The 129 
cases were equally divided into training and validation sets, each of 36 cases. The distribution of 130 
RS in the training set was shown to be significantly equivalent to the distribution of RS in the 131 
validation set using the Kolmogorov–Smirnoff test (P = 0.88).  132 
RNA was extracted from 10µm-thick sections of archival paraffin blocks using 133 
RecoverAll™ Total Nucleic Acid Isolation Kit (Life Technologies, Grand Island, NY) according 134 
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to the manufacturer’s instructions. The quality of RNA was assessed using the Nanodrop® ND-135 
1000 spectrophotometer (ThermoScientific, Wilmington, DE). Total RNAs were reverse-136 
transcribed using the High Capacity cDNA Reverse Transcription kit (Life Technologies) 137 
according the manufacturer’s instructions.  138 
 139 
Selection of the TaqMan qRT-PCR Assays  140 
Specific target sequences for each probe from Human Genome U133A 2.0 Array were obtained 141 
using NetAffx Analysis Center (http://www.affymetrix.com/analysis/index.affx). Target 142 
sequences were aligned to the appropriate mRNA reference sequence (REFSEQ) accession 143 
number using NCBI BLAST (Basic Local Alignment Search Tool) 144 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and accessed the consensus sequence through the NCBI 145 
Entrez nucleotide database.  146 
Using UMapIt mapping tool of Applied Biosystems (ABI, Foster City, CA), the 147 
Affymetrix probe IDs were mapped to TaqMan assays specific to each sequence. TaqMan 148 
assays, where necessary custom-designed using Primer Express (Applied Biosystems), were 149 
tested for the amplification efficiency based on the ABI defined criteria. Control RNA (Universal 150 
Human Reference RNA; Stratagene) and FFPE samples were used to test the efficiency of the 151 
probes. Based on the observed efficiency, probes were selected for custom array microfluidic 152 
cards (TaqMan assays; Suppl. Table S3). 153 
 154 
qRT-PCR Analysis using Custom Arrays 155 
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TaqMan reactions were performed in triplicates using custom array microfluidic cards preloaded 156 
with TaqMan Gene Expression Assays containing 17 genes (12 discriminant genes and five 157 
reference genes) on an ABI Prism 7900HT Fast Real-Time platform according to the 158 
manufacturer’s instructions (Suppl. Table S3). ACTB, TFRC, GUS, RPLPO, and GAPDH were 159 
used as endogenous reference controls for normalization. Delta threshold cycle values for each of 160 
the 12 genes of interest were normalized using these endogenous controls according to the 161 
method of Applied Biosystems DataAssist™ Software v3.0. 162 
 163 
Construction of a genomic signature from gene expression measurements  164 
The methodology for construction of a genomic signature is described in detail in Supplementary 165 
Methods. 166 
 167 
Statistical analyses 168 
All statistical analyses were performed using R (http://www.r-project.org). Mixture models were 169 
fit using the package mclust28, 29, and survival analysis was performed with the survival package. 170 
The significance of a Cox proportional hazard (CPH) model is assessed with the P value of the 171 
logrank score test. The significance of a multivariate CPH over a CPH using a subset of the 172 
variables is measured with a Chi-squared test of the log-likelihoods. The proportional hazard 173 
condition is tested with the cox.zph function.  174 
 The prognostic significance of genomic signatures was compared using concordance 175 
index30, 31. The concordance index estimates the probability that, for a random pair of patients, 176 
the patient with earlier recurrence has higher score than the patients with either later or no 177 
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recurrence. The concordance index is a number between 0 and 1, defined more formally in 178 
Supplementary Methods. A concordance index greater than 0.5 indicates that the prognostic 179 
score is more significant that random chance. A confidence interval for concordance index was 180 
computed by resampling. A function from the survcomp package was used to compute 181 
concordance index. 182 
 183 
Computation of alternative genomic signatures 184 
To compare the prognostic significance of EarlyR with that of Oncotype DX, Mammaprint and 185 
Risk of Recurrence (ROR) Score, we compute surrogates of these signatures in METABRIC 186 
using the Bioconductor genefu package32.  187 
To compute Oncotype DX, we select probes in the IlluminaHumanv3 platform 188 
representing the 16 target genes in the panel3; for genes represented by multiple probes we select 189 
the probe with the highest variance in the ER+ METABRIC cohort, the recommended method in 190 
genefu. Probes representing all 16 target genes were identified, and the Recurrence Score was 191 
computed using the package’s function for that purpose. To accommodate for possible 192 
differences between expression values assessed by the Illumina platform and the native RT-PCR 193 
platform, we computed surrogate low risk, intermediate risk, and high risk strata so that the 194 
percentages in ER+, LN- patients match those found in NSABP B-143.  195 
  Mammaprint was derived from a 70-gene signature4, and referred to as GENE70 in 196 
genefu. GENE70 was originally computed using 70 array probes from the Agilent Hu25K array 197 
platform, of which 56 were associated with 52 unique EntrezIDs. For these 52 EntrezIDs, 198 
Illumina probes were selected that had the highest variance in METABRIC. From these probes 199 
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on July 18, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11 
and the appropriate genefu function a continuous GENE70 Score was computed. The GENE70 200 
stratification into low risk and high risk groups was computed using a GENE70 Score threshold 201 
that produces a low risk group containing 50% of the ER+, LN-, METABRIC cohort.  202 
 The ROR Score6 was computed in METABRIC using the appropriate genefu function 203 
with the default arguments. The ROR stratification was created with the same percentages in 204 
low, intermediate and high risk groups for ER+ METABRIC as for transATAC33, specifically, 205 
55%, 25%, 20%, respectively. 206 
 207 
  208 
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RESULTS 209 
Discovery of EarlyR: a continuous score and prognostic stratification using expression values 210 
of ESPL1, MKI67, SPAG5, PLK1 and PGR 211 
To identify the gene signature, an integrative approach consisting of analysis of in silico data and 212 
FFPE samples was used (Suppl. Figure S1). This was undertaken to ensure stability of the probes 213 
in fresh and frozen tissue and across multiple analytical platforms. Prior analysis of GSE4922 214 
(UPPS), GSE6532 (OXFD, GUYT), GSE7390 (TRANSBIG), GSE9195 (GUYT2), and 215 
GSE11121 (MZ)13 led to the identification of a set of 12 genes (ESPL1, CDC45L, PLK1, 216 
CENPA, MKI67, SPAG5, CDT1, PGR, CXCL9, PHLPP1, CDC6, PRPF4) that provided 217 
prognostic information in these ER+ breast cancer samples. To determine the feasibility of using 218 
these probes for a prognostic signature with FFPE tissue, we performed a qRT-PCR analysis of 219 
these 12 genes in a training set of 36 ER+ breast cancer FFPE samples with known Oncotype DX 220 
RS (Suppl Table S2). For each of the 12 target genes on the qRT-PCR array, risk scores were 221 
derived using the ∆-CT values from the training set of 36 samples (Supplementary Methods). 222 
The nine genes whose risk scores were significantly predictive of TAILORx risk group (p-value 223 
of the linear model < 0.05) were considered for further gene signature development.  224 
The nine genes (ESPL1, CDC45L, PLK1, CENPA, MKI67, SPAG5, CDT1, PGR, 225 
CXCL9) identified by the above method, were further analyzed for inclusion in a multi-gene 226 
signature in the Affymetrix training dataset of 266 ER+/lymph node negative (LN–) breast 227 
cancers obtained from GSE349417 and GSE739018. The incremental impact of addition of each 228 
gene to the prognostic score was analyzed starting with the most prognostic gene, ESPL1. Next, 229 
the top 2 genes (ESPL1 and SPAG5) were combined to derive a 2-gene signature score 230 
(Supplementary Methods). This process was continued until the multigene score with maximally 231 
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significant results was obtained (Supplementary Methods). This signature, EarlyR score, uses the 232 
genes ESPL1, MKI67, SPAG5, PLK1, and PGR.  Specifically, EarlyR score was computed in the 233 
Affymetrix-based cohorts using a gene signature derived from the expression of the following 5 234 
probes: 204817_at (ESPL1), 212022_s_at (MKI67), 203145_at (SPAG5), 202240_at (PLK1), 235 
208305_at (PGR). 236 
 237 
Concordance of EarlyR and RS in FFPE samples 238 
To reconfirm the ability of EarlyR to assess risk in FFPE tissues, we showed that the Oncotype 239 
DX recurrence score RS is linearly dependent on the EarlyR stratification (P = 0.001, Suppl 240 
Figure S2) in the FFPE validation set (Table S2). Samples were further separated into risk groups 241 
with respect to RS using the Oncotype DX thresholds3 and the TAILORx thresholds34. We found 242 
a significant concordance between EarlyR risk strata and Oncotype DX risk strata (P = 0.004) 243 
and TAILORx risk strata (P = 0.002). This confirms the feasibility of using EarlyR for the 244 
analysis of FFPE samples.  245 
 246 
Validation of EarlyR in Affymetrix and METABRIC cohorts 247 
The EarlyR score and the EarlyR strata, EarlyR-Low (EarlyR ≤ 25), EarlyR-Int (25 < EarlyR ≤ 248 
75), and EarlyR-High (75 < EarlyR) were computed from the score values in all validation 249 
cohorts (GSE1209319, GSE653220, GSE203421, GSE1112122, GSE1770523 and METABRIC). 250 
This computation was performed blind to all clinical features of the samples (Supplementary 251 
Methods). 252 
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EarlyR score classified a large majority of samples as either low risk or high risk in 253 
Affymetrix (Figure 1a) and METABRIC (Figure 1b) validation cohorts. Moreover, the 254 
percentage of samples in each stratum was comparable across subgroups defined by clinical 255 
traits (Suppl. Table S4). Specifically, approximately 65% (63%-71%) of samples were classified 256 
as EarlyR-Low in ER+, LN- and LN+ samples in both cohorts (Suppl. Table S4) and 71% of ER+, 257 
HER2- samples in METABRIC were EarlyR-Low. Together low risk and high risk categories 258 
defined by EarlyR accounted for over 85- 88% of patients in all subgroups with only 12-15% of 259 
samples being classified as of intermediate risk.  260 
 The prognostic significance of EarlyR stratification and EarlyR continuous score were 261 
assessed in ER+ overall and subgroups defined by lymph node status, HER2 status and tumor 262 
size for Affymetrix validation cohort and METABRIC cohort. EarlyR score and stratification 263 
were significantly prognostic in all subgroups (Table 1, Figure 2, Figure S3).  264 
 In contemporary treatment regimens, almost all ER+ breast cancer patients are treated 265 
with hormone therapy. EarlyR stratification and continuous score were both prognostic in 266 
hormone therapy treated patients in Affymetrix validation cohort (Table 1, Figure 3a,b, Figure 267 
S4a,b) . Also, among those ER+ patients with LN- disease who were treated with hormone 268 
therapy, EarlyR stratification and continuous score were both prognostic in Affymetrix 269 
validation cohort and METABRIC (Table 1, Figure 3c,d, Figure S4c,d). In ER+, LN- patients 270 
treated with hormone therapy in Affymetrix validation cohort, the EarlyR-Low patients (78%) 271 
had probability of distant relapse after 8 years 0.91 (95%CI 0.78 – 0.94).  272 
 In addition to being prognostic of DRFI, in METABRIC, EarlyR stratification was 273 
prognostic of 8-year BCFI in all ER+ patients (HR of High v Low = 2.3 (95%CI 1.8-2.9), Figure 274 
4a), ER+, LN- patients (HR of High v Low = 1.9 (95%CI 1.4-2.8), Figure 4b); ER+, LN+ (HR of 275 
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High v Low = 2.6 (95%CI 2.0-3.6), Figure 4c); and ER+ patients, treated with hormone therapy 276 
(HR of High v Low = 2.3 (95%CI 1.7-3.0), Figure 4d).  277 
 278 
EarlyR prognostic significance in multivariate analysis including clinico-pathological 279 
variables 280 
The independence of EarlyR from clinico-pathological variables was assessed using multivariate 281 
Cox models in accordance with the REMARK recommendations35. Adding EarlyR to each of LN 282 
status, tumor size (binary and continuous), patient age (binary), and tumor grade, significantly 283 
increased the prognostic significance of the clinical variable (Suppl. Table S5) in METABRIC. 284 
In a Cox model including LN, binary tumor size, binary age and grade, the addition of EarlyR, 285 
significantly improved on the prognostic significance of the clinically-based model (P = 1.1 x 10-286 
12 for the Chi-squared statistic of the log-likelihoods). This provided strong evidence that EarlyR 287 
offers prognostic information that cannot be derived from clinico-pathological variables. 288 
 In multivariate Cox models (using 8-year DRFI) including stratified EarlyR and each of 289 
tumor size, age, and tumor grade, within ER+, LN- METABRIC samples, only binary tumor size 290 
is statistically significant (P = 0.0045) in addition to EarlyR. We further analyzed the effect of 291 
EarlyR prognostic significance separately in small and large tumors. First, there is no interaction 292 
effect for EarlyR stratification and tumor size; i.e., the hazard ratio for EarlyR–High versus 293 
EarlyR–Low is not significantly different between small (≤ 2 cm) and large (> 2 cm) tumors. In 294 
the cohort of ER+, LN-, METABRIC tumors of size ≤ 2cm, EarlyR stratification is prognostic of 295 
8-year DRFI (HR High v Low 2.2 (95%CI 1.2-4.1)) with 8-year expected survival probabilities 296 
0.89 (95%CI 0.86 – 0.93), 0.78 (95%CI 0.67 – 0.91), 0.79 (95%CI 0.70 – 0.89) for EarlyR-Low, 297 
EarlyR-Int, EarlyR-High, respectively.  In the corresponding set of patients with tumors > 2cm, 298 
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EarlyR stratification is prognostic of 8-year DRFI (HR High v Low 2.1 (95%CI 1.2-3.6)) with 8-299 
year expected survival probabilities 0.84 (95%CI 0.79 – 0.89), 0.63 (95%CI 0.50 – 0.79), 0.71 300 
(95%CI 0.61 – 0.82) for EarlyR-Low, EarlyR-Int, EarlyR-High, respectively. 301 
 302 
 303 
Prognostic significance of EarlyR was superior or comparable to other genomic assays 304 
Surrogates for Recurrence Score3, GENE70 (a precursor of Mammaprint)4, 5 and Risk of 305 
Recurrence Score6, and stratified versions, were computed for the METABRIC cohort using the 306 
genefu R package (32and Methods.) The concordance index 30, 31 was used to compare the 307 
prognostic significance of these tests as continuous scores, as has been previously done for 308 
prognostic assays16. These comparisons (Supplementary Figure S5) showed that the concordance 309 
index was highest for EarlyR followed by Recurrence Score, GENE70 and ROR scores, in that 310 
order, although this difference was not statistically significant by the 95% confidence intervals. 311 
This establishes that EarlyR is at least as prognostic as surrogates of these other signatures. 312 
 Expected survival probabilities (8-year DRFI) for stratified versions of EarlyR and the 313 
Recurrence Score, Gene70 and ROR were computed in the ER+, LN-, HER2- METABRIC 314 
cohort (Table S6). The expected survival probability in EarlyR-Low is nearly the same as for the 315 
other signatures, although EarlyR-Low contains 72% of the samples, and the low risk groups for 316 
Recurrence Score, GENE70 and ROR are 55%, 55%, 62%, respectively. 317 
 318 
 319 
  320 
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DISCUSSION: 321 
The decision to use adjuvant chemotherapy to treat early stage breast cancer must balance the 322 
reduced risk of metastasis with chemotherapy’s toxic effects. Increasingly, tests that analyze 323 
gene expression patterns in primary tumors are being used to guide this decision. Herein, we 324 
have developed an assay wherein the EarlyR score (0 – 100) is defined by combining the risk 325 
scores of the 5 panel genes using a non-linear formula. The computation of the EarlyR score, and 326 
the resulting stratification into risk groups, is intended to offer the convenience of discrete 327 
classification (EarlyR-High or EarlyR-Low) while dependably identifying a small subset of 328 
patients (EarlyR-Int) whose risk classification is uncertain. In contrast to Oncotype DX, which 329 
has an intermediate risk group of at least 35% in most studies, EarlyR-Int consistently contains at 330 
most 15% of samples. Thus, EarlyR offers a definitive prognosis for significantly more patients 331 
than Oncotype DX.   332 
EarlyR is further distinguished by identifying a large majority of ER+, LN-, HER2- 333 
patients as low risk (72% in METABRIC). In contrast, in several studies, at most 59% of ER+, 334 
LN- patients are classified as low risk by Oncotype DX 12, 16, 36. In spite of the larger low risk 335 
stratum for EarlyR, using surrogates of Recurrence Score, Mammaprint and Risk of Recurrence 336 
in METABRIC, we showed that EarlyR is at least as significant as a prognostic tool using 337 
concordance index and expected survival.  338 
EarlyR-Int consists of samples in which EarlyR score is rising sharply from the low-risk 339 
group, to the high-risk group; i.e., these are samples that straddle the boundary between good and 340 
poor prognosis. In multiple Kaplan-Meier analyses, we found that the expected survival 341 
probability for EarlyR-Int was comparable to that of EarlyR-High (Fig 2, 3). Further studies in 342 
well annotated clinical trial cohorts with determine the need for this intermediate-risk category.  343 
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In the ER+, LN-, HER2- METABRIC samples, the 8-year distant recurrence free survival 344 
estimate for the EarlyR low risk stratum was 88%. This estimated survival percentage is 345 
markedly lower than that computed for Recurrence Score and Risk of Recurrence in transATAC 346 
16 or for Mammaprint in the MINDACT trial15. However, the low risk strata for surrogates of 347 
these other signatures in the same subset of METABRIC are between 87% and 89% (Suppl 348 
Table S6). This is likely due to the fact that only 52% of these patients received hormone 349 
therapy, and 54% of them had tumors > 2 cm in diameter. In contrast, in MINDACT, all ER+ 350 
patients were recommended for hormone therapy and only 28% of tumors (including both LN- 351 
and LN+) were > 2 cm.  352 
Tumor size has been found to be significantly prognostic independent of Risk of 353 
Recurrence6, Recurrence Score37, and EndoPredict38.  The commercial Prosigna score combines 354 
Risk of Recurrence with tumor size to form a single score, and EPclin combines EndoPredict and 355 
tumor size. We found that tumor size was also significantly prognostic independent of EarlyR in 356 
the ER+, LN- METABRIC cohort. To elucidate the combined prognostic significance of EarlyR 357 
and tumor size, we reported the prognostic significance of EarlyR separately in tumors ≤ 2 cm 358 
and tumors > 2 cm. We feel that conflating size and a genomic score into a single score confuses 359 
the independent effects of the two risk factors.  360 
Each gene in the EarlyR panel, ESPL1, MKI67, SPAG5, PLK1, and PGR, has a role in 361 
multiple processes related to ER+ breast cancer progression and treatment response. ESPL1, 362 
which is critical for the timely separation of sister chromatids during anaphase, has been found to 363 
be disproportionately elevated in luminal B tumors, and a risk factor independent of PAM50, 364 
Recurrence Score, Mammaprint and EndoPredict39. MKI67 is a well-studied biomarker for 365 
proliferation. Elevated expression of SPAG5, which is associated with the mitotic spindle 366 
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apparatus, is predictive of sensitivity to cytotoxic chemotherapy in breast cancer40, 41. PLK1 is 367 
known to promote hormone-independent ER transcription and growth42, as well as being 368 
associated with mutations of TP5343. The role of the hormone receptor PGR in progression of 369 
breast cancer is well established. 370 
Prognostic signatures for ER+ breast cancer, including EarlyR, were developed to assist 371 
physicians in selecting patients for hormone therapy alone or combined with systemic 372 
chemotherapy (see NCCN Guidelines, Breast Cancer44). Studies are planned to build evidence 373 
that patients identified as high risk by EarlyR are good candidates for chemotherapy, while those 374 
in EarlyR-Low are unlikely to benefit from chemotherapy. 375 
There are a number of limitations of the current study. The major limitation is that all of 376 
the analyses were performed in a retrospective manner using in silico data obtained from several 377 
studies with only 2,775 samples. These studies had variable methods of pre-analytical tissue 378 
preparation, analytical techniques (U133A, and IlluminaHuman-v3) and statistical analytic 379 
methods. Moreover, the samples were from patients not treated under current standards for ER+ 380 
breast cancer in that many did not receive hormone therapy or chemotherapy.  However, in spite 381 
of these, the EarlyR score showed remarkable stability in predicting outcomes. Another 382 
important issue is the small number of FFPE samples used in the study. This analysis was meant 383 
to provide a proof of principle for an assay to execute EarlyR testing with qRT-PCR using FFPE 384 
tissues. Additional studies are planned using clinical trial samples to validate the results of the 385 
studies presented herein.  386 
 387 
 388 
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Conclusion 389 
EarlyR assay is a risk score that classified at least 85% of ER+ patients as high or low risk. The 390 
intermediate risk category contained at most 15% of patients, approximately half that observed in 391 
other assays. EarlyR classified significantly more patients (72% of ER+, LN-, HER2-) as low risk 392 
compared to other signatures (Oncotype DX RS, Mammaprint, and PAM50 ROR), without 393 
apparent loss in prognostic significance. We showed that the prognostic significance of EarlyR is 394 
not improved by the addition of age or grade in ER+, LN- tumors, but tumor size is independently 395 
significant. Further independent validation in well-annotated cohorts of patients treated with 396 
current standards for hormone therapy is necessary to determine EarlyR’s clinical utility. 397 
 398 
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Clinical Practice Points 408 
 409 
• There is a need for better gene signatures in ER+ breast cancer as current assays identify 410 
a percent of patients as having uncertain risk of recurrence.    411 
• The goal of this study was to establish the utility of a novel 5-gene signature for ER+ 412 
breast cancer and compare it with existing assays. 413 
• The 5-gene signature, EarlyR, performs similarly to existing commercial assays in 414 
concordance analyses..  415 
• EarlyR assay is a risk score that classified at least 85% of ER+ patients as high or low 416 
risk. The intermediate risk category contained at most 15% of patients, approximately 417 
half that observed in other assays  418 
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Table 1. Significance and expected survival of EarlyR strata with respect to 8-year DRFI in selected subgroups 
 
 P value for 
EarlyR score 
HR for 
EarlyR 
score* 
P value for 
EarlyR strata 
HR of 
EarlyR-
High to 
EarlyR-Low 
Expected survival with respect to 8-year DRFI 
(95%CI) 
     EarlyR-Low EarlyR-Int EarlyR-High 
METABRIC        
All ER+ < 2.2 x 10-16§ 1.7 (1.5-
2.0) 
< 2.2 x 10-16 †  2.6 (2.0-3.3) 0.82 (0.79-
0.85) 
0.62 (0.54-
0.70) 
0.61 (0.56-
0.67) 
ER+, LN- 3.6 x 10-6 1.6 (1.3-
1.9) 
3.5 x 10-7  2.3 (1.5-3.4) 0.87 (0.84-
0.90) 
0.69 (0.60-
0.79) 
0.75 (0.69-
0.82) 
ER+, LN+ 8.3 x 10-14 1.8 (1.5-
2.1) 
7.3 x 10-12  2.9 (2.1-3.9) 0.75 (0.71-
0.80) 
0.53 (0.42-
0.66) 
0.44 (0.36-
0.54) 
ER+, HER2- 4.0 x 10-15 1.8 (1.5-
2.1) 
2.2 x 10-14 2.6 (2.0-3.5) 0.83 (0.80-
0.86) 
0.61 (0.53-
0.71) 
0.63 (0.56-
0.71) 
ER+, size ≤ 2cm 5.2 x 10-7 1.8 (1.4- 2.9 x 10-6 2.8 (1.8-4.3) 0.88 (0.84- 0.74 (0.65- 0.70 (0.62-
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2.2) 0.91) 0.85) 0.79) 
ER+, size > 2cm 8.5 x 10-11 1.6 (1.4-
1.9) 
5.1 x 10-10 2.3 (1.7-3.1) 0.77 (0.83-
0.81) 
0.53 (0.44-
0.65) 
0.54 (0.47-
0.62) 
ER+, with 
hormone therapy 
1.5 x 10-12 1.7 (1.4-
1.9) 
2.2 x 10-11 2.5 (1.9-3.3) 0.80 (0.77-
0.84) 
0.62 (0.54-
0.72) 
0.58 (0.52-
0.66) 
ER+, LN-, with 
hormone therapy 
0.01 1.4 (1.1-
1.9) 
0.03 2.0 (1.1-3.4) 0.86 (0.82-
0.91) 
0.79 (0.68-
0.92) 
0.77 (0.68-
0.86) 
Affymetrix 
validation 
       
All ER+ 8.8 x 10-15 1.7 (1.5-
1.9) 
3.5 x 10-14 2.7 (2.1-3.5) 0.81 (0.78-
0.84) 
0.5 (0.27-
0.93) 
0.58 (0.51-
0.65) 
ER+, LN- 7.3 x 10-15 1.8 (1.6-
2.1) 
1.4 x 10-13 3.2 (2.4-4.5) 0.85 (0.82-
0.88) 
0.63 (0.37-1) 0.59 (0.52-
0.67) 
ER+, LN+ 0.048 1.3 (1-1.6) 6.7 x 10-4 1.6 (1-2.7) 0.66 (0.58-
0.75) 
NA 0.53 (0.40-
0.69) 
ER+, with 1.9 x 10-6 1.6 (1.3- 2.3 x 10-6 2.5 (1.7-3.7) 0.83 (0.79- 0.5 (0.23-1) 0.63 (0.54-
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hormone therapy 1.9) 0.87)  0.73) 
ER+, LN-, with 
hormone therapy 
3.6 x 10-6 1.9 (1.4-
2.6) 
2.4 x 10-5 3.7 (2.0-6.6) 0.91 (0.78-
0.94) 
0.75 (0.43-
1.0) 
0.70 (0.59-
0.82) 
* Hazard ratio for EarlyR score in increments of 50 
§ chi-squared statistic with df = 1 is 76 
† chi-squared statistic with df = 2 is 78   
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Figure legends 
 
 
 
Figure 1. The continuous EarlyR score is plotted with respect to quantiles of the score in (a) the 
ER+ samples in the Affymetrix validation cohort, and (b) ER+ samples in the METABRIC 
cohort. Points are colored according to the risk strata EarlyR-Low (EarlyR ≤ 25), EarlyR-Int (25 
< EarlyR ≤ 75), and EarlyR-High (75 < EarlyR). Dotted vertical lines indicating the boundaries 
between the strata are plotted, along with the percentages of samples in each stratum. 
 
Figure 2. Kaplan-Meier survival curves with respect to distant recurrence are plotted for the 
EarlyR risk strata for cohorts (a) ER+ Affymetrix validation (n = 991),  (b) ER+ METABRIC (n = 
1518), (c)  ER+, LN- Affymetrix validation (n = 782), (d) ER+, LN- METABRIC (n = 829), (e)  
ER+, LN+ Affymetrix validation (n = 209), (f)  ER+, LN+ METABRIC (n = 689). The numbers of 
samples in each stratum are reported in the legends. The 8-year expected survival with respect to 
DRFI for each cohort and stratum is reported in Table 1. 
 
Figure 3. Kaplan-Meier survival curves with respect to distant recurrence are plotted for the 
EarlyR risk strata for the following cohorts treated with hormone therapy (HT): (a) ER+ 
Affymetrix validation, HT treated (n = 559); (b) ER+ METABRIC, HT treated (n = 1088); (c) 
ER+, LN- Affymetrix validation, HT treated (n = 369); (d) ER+, LN- METABRIC, HT treated (n 
= 445). The percentages of the subgroups in EarlyR strata are reported in figure legends. The 8-
year distant relapse-free survival probabilities for the EarlyR risk strata are reported in Table 1. 
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on July 18, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 29 
 
Figure 4. Kaplan-Meier survival curves with respect to BCFI are plotted for the EarlyR risk 
strata for the following subgroups of METABRIC samples: (a) ER+ (n = 1518); (b) ER+, LN- (n 
= 829); (c) ER+, LN+ (n = 689); (d) ER+, HT treated (n = 1088).  The 8-year breast cancer-free 
survival probabilities for the EarlyR risk strata are as follows. (a) EarlyR-Low: 0.79 (95%CI 0.76 
– 0.82), EarlyR-Int: 0.56 (95%CI 0.49 – 0.64), EarlyR-High: 0.58 (95%CI 0.53 – 0.64); (b) 
EarlyR-Low: 0.83 (95%CI 0.80 – 0.87), EarlyR-Int: 0.63 (95%CI 0.53 – 0.74), EarlyR-High: 
0.71 (95%CI 0.65 – 0.79); (c) EarlyR-Low: 0.73 (95%CI 0.69 – 0.78), EarlyR-Int: 0.49 (95%CI 
0.39 – 0.62), EarlyR-High: 0.42 (95%CI 0.34 – 0.52); (d) EarlyR-Low: 0.78 (95%CI 0.75 – 
0.81), EarlyR-Int: 0.58 (95%CI 0.50 – 0.68), EarlyR-High: 0.57 (95%CI 0.50 – 0.64). 
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Supplementary Methods 
 
Multistate method for construction of a signature score from a panel of genes.  
Gene risk scores. Foundational to our approach to calculating a multigene signature is concept of 
a gene risk score, derived from that of a multistate gene 1, as follows. Given the expression 
values of a gene in a sample set S, let M be the Gaussian mixture model fit with minimal BIC. M 
partitions the expression values into intervals, most typically, two intervals consisting of the 
expression values above and below a threshold. Distinguish as the high-risk component the 
interval which has the greater proportion of cases that recur. Define as the gene’s risk score the 
probability that a sample is in the high-risk component, as determined by the model M.  
 When the mixture model M defines more than two intervals, it defines more than one 
possible threshold between high and low expression values. In this case, there are several 
possible risk scores for this gene. In defining a prognostic signature using these methods, the 
discovery process will select the risk score that results in the most significant signature.  In the 
discovery process, if the model M for a specific gene has only one component, that gene will be 
eliminated from consideration for the panel. 
 It bears emphasizing that the gene risk score is derived from fitting a model to the gene’s 
expression values. There is no algebraic formula for computing the risk score. The computer 
program for executing the model fit is proprietary.     
  
Multistate gene signatures. Given panel genes g1,…,gn, for a multistate gene signature, derived 
through the discovery process given below, and a cohort of patient samples, C, for which 
expression values of g1,…,gn have been assayed, the multistate gene signature score is computed 
as follows. 
1. For each panel gene gi,, let ri be the gene risk score for gi in C; 
2. The signature score S is 1 minus the product of all numbers of the form (1 - rirj), as (i,j) 
range over all possible distinct pairs from 1 to n. For convenience, S is scaled to 0 – 100. 
(If we interpret ri as the probability that a sample is in a high-risk state due to gene gi, 
then S is the probability that some pair of panel genes are in high-risk states.) 
3. Given the continuous score S, discrete risk strata for the signature are defined as Low 
Risk (S ≤ 25), Intermediate Risk (25 < S ≤ 75), High Risk (75 < S). 
Going forward, it is important to bear in mind that  
• The computation of the score S in a cohort of patient samples, is independent of the 
technology used to measure gene expression, and all clinical data; 
• The signature risk strata are computed directly from the score values, thus are also 
independent of clinical data. 
 
Discovery of a multistate signature. To discover a multistate gene signature, a training cohort of 
samples with whole-genome expression data is selected. From the expression values for all genes 
assayed, all possible gene risk scores are computed and are individually evaluated for prognostic 
significance using the score statistic of a Cox proportional hazards model. Ranking these by 
individual significance, sets of genes are combined as possible panels and the resulting 
signatures computed (see item 2 above). A set of panel genes is selected whose signature is 
maximally prognostic, as computed for Cox proportional hazards models.  More specifically, if 
Pi is the signature produced with the i highest ranked genes, we select as the signature the 
minimal i such that the Cox proportional hazards model with variables Pi and Pi+1 is not 
statistically more significant than that with the variable Pi, compared using log-likelihoods.    
 
Computation of multistate gene signature score for samples not in the training cohort. In the 
training cohort, gene risk scores are computed using the model fitting process described above. 
To compute the signature score for a new sample, the expression values for the panel genes are 
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assayed and compared to the expression values in a reference set of samples (such as the training 
cohort). A lookup table is used to estimate the risk score values for each of the pane genes. 
Subsequently, the signature score values are computed as described above.  
  
 
Concordance index 
The concordance index for a continuous score S in a set of samples X with survival data event 
and time, is computed as follows. A pair, i, j from X is called evaluable if at least 1 incurred an 
event, and if only one incurs an event (say i) then the censoring time of j is later than the event 
time for i. For each evaluable pair i and j compute a number c(i,j) to be 1 if i relapses prior to the 
relapse or follow-up time of j and S(i) < S(j); c(i,j) is also 1 if the preceding clause is true after 
switching i and j.   The concordance index for S in X is then the mean of the numbers c(i,j) over 
all evaluable pairs. If S is a stratification rather than a continuous score, the formula is adjusted 2. 
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Supplementary Tables 
Table S1. Characteristics of the patients in the microarray datasets used in this study 
 Affymetrix METABRIC (ER+) 
 training* validation†  
number 266 991 1518 
lymph node (-/+) 266/0 782/209 829/689 
grade (1/2/3/NA) 80/141/43/2 32/99/37/823 166/712/570/70 
size (≤ 2 cm/> 2 cm/NA) 162/102/0 90/113/788 669/835/14 
Age (< 50/≥ 50/NA) 110/156/0 42/161/788 247/1271/0 
8-year distant relapse event 
(no/yes/NA) 
220/46/0 757/226/8 1190/327/1 
BCFI event 
(no/yes/NA) 
NA NA 1142/375/1 
HER2 status (+/-/NA) NA NA 268/1245/5 
Hormone therapy (yes/no) 15/251 559/432 1088/430 
Chemotherapy (yes/no) 0/266 0/991 164/1354 
* GSE3494, GSE7390 
† GSE12093, GSE6532 (Oxford cohort), GSE2034, GSE11121, GSE17705 
 
 
Table S2. Characteristics of the patients in the FFPE datasets used in this study 
 FFPE training set FFPE validation set 
Number 36 36 
Age (< 50/ ≥ 50 15/21 15/21 
Grade (1/2/3) 8/21/7 3/24/9 
Size (≤ 2cm / > 2 cm) 24/12 29/7 
TAILORx risk groups 
(LR/IR/HR) 
4/18/14 6/15/15 
Oncotype Dx risk groups 
(LR/IR/HR) 
9/16/11 9/15/12 
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Table S3 Probes used for the development of quantitative PCR based EarlyR assay development 
(TaqMan Custom Array Format) 
 
Gene Symbol Assay ID Amplicon length 
MKI67 Hs04260396_g1 64 
SPAG5 Hs04260397_s1 60 
ESPL1 Hs00901789_g1 62 
CDC6 Hs00154374_m1 77 
CDC45L Hs00907337_m1 62 
CDT1 Hs00368864_m1 59 
PLK1 Hs00983233_g1 61 
PHLPP1 Hs01597874_m1 90 
CENPA Hs00903938_g1 62 
CXCL9 Hs00171065_m1 60 
PGR Hs01556792_m1 77 
PRPF4 Hs00992013_g1 74 
ACTB *** Hs00357333_g1 77 
TFRC *** Hs00951083_m1 66 
GUS *** Hs99999908_m1 81 
RPLPO *** Hs99999902_m1 105 
GAPDH ***   control in the array 
 
Table S4. Distributions of EarlyR risk strata in clinically defined subsets 
 
 n EarlyR-Low EarlyR-Int EarlyR-High 
METABRIC     
All ER+ 1518 66% 13% 21% 
LN- 829 67% 12% 21% 
LN+ 689 64% 15% 21% 
Size ≤ 2cm 669 70% 12% 18% 
Size > 2cm 835 63% 14% 23% 
HER2- 1245 71% 12% 16% 
     
Affymetrix 
validation 
    
All ER+ 991 75% 1% 24% 
LN- 782 76% 1% 23% 
LN+ 209 70% 1% 29% 
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Table S5. Prognostic significance (8-year DRFI) of EarlyR in excess of clinical features in 
multivariate analysis in ER+ METABRIC cohort 
 
Feature p-value of 
feature 
p-value of EarlyR in 
excess of feature* 
LN < 10-16  § 3.3 x 10-16 
size (continuous) < 10-16  ¶ 8.6 x 10-14 
size ( ≤ 2 cm / > 2 cm) 9.3 x 10-11 1.9 x 10-14 
age (< 50 / ≥ 50) 0.45 3.3 x 10-16 
grade  3.2 x 10-5 2.5 x 10-12 
LN + size + age + grade < 10-16  † 1.6 x 10-12 
* p-value of likelihood ratio of Cox proportional hazard model additively including EarlyR strata 
in comparison to model with only the clinical feature(s). 
§ Chi-squared statistic (df = 1) is 127 
¶ Chi-squared statistic (df = 1) is 78 
† Chi-squared statistic (df = 5) is 87 
 
 
Table S6. Expected survival probabilities (8-year DRFI) for strata of surrogates of genomic 
assays in LN-, HER2- METABRIC cohort 
Test Expected 8-year survival probability (DRFI) (95%CI) 
Low risk Intermediate risk High risk 
EarlyR  0.88 (0.84 - 0.91) 0.68 (0.58 – 0.80) 0.77 (0.69 – 0.86) 
Recurrence Score 0.89 (0.86 – 0.93) 0.82 (0.76 – 0.89) 0.72 (0.65 – 0.80) 
GENE70 0.89 (0.85 – 0.92) NA 0.77 (0.73 – 0.83) 
Risk of Recurrence 0.87 (0.84 – 0.91) 0.79 (0.72 – 0.86) 0.76 (0.67 – 0.86) 
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Supplementary Figures 
 
Figure S1.  
Flowchart detailing the steps associated with the development of the EarlyR gene signature. 
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Figure S2.  
For samples from the FFPE validation set (n = 36), Oncotype DX Recurrence Score (RS) is 
linearly dependent on EarlyR strata (p = 0.001). Samples are also colored by TAILORx risk 
group. 
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Figure S3. Estimated distant relapse-free survival eight years after diagnosis is plotted by 
quantiles of the continuous EarlyR score for (a) ER+ Affymetrix validation (n = 991),  (b) ER+ 
METABRIC (n = 1518), (c)  ER+, LN- Affymetrix validation (n = 782), (d) ER+, LN- 
METABRIC (n = 829), (e)  ER+, LN+ Affymetrix validation (n = 209), (f)  ER+, LN+ 
METABRIC (n = 689).  EarlyR stratum membership is indicated by the color of the point. 
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Figure S4. Estimated distant relapse-free survival eight years after diagnosis is plotted by 
quantiles of the continuous EarlyR score for the following cohorts treated with hormone therapy 
(HT): (a) ER+ Affymetrix validation, HT treated (n = 559); (b) ER+ METABRIC, HT treated (n 
= 1088); (c) ER+, LN- Affymetrix validation, HT treated (n = 369); (d) ER+, LN- METABRIC, 
HT treated (n = 445). 
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Figure S5. Concordance indices of genomic signatures with respect to 8-year DRFI are plotted 
for ER+ METABRIC cohort. Square points indicate the concordance indices and lines are the 
95% confidence intervals. Continuous scores were evaluated for each of EarlyR, Recurrence 
Score, GENE70 and Risk of Recurrence. All of these tests are statistically significant since the 
concordance index confidence intervals are all entirely greater than 0.5. The highest concordance 
index is for EarlyR (0.664).  
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